App-Quantinova.ai

Molecular characterization of circulating tumor cells (CTCs) of patients with neuroendocrine prostate cancer (NEPC).

Himisha Beltran - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Heterogeneity of prostate-specific membrane antigen (PSMA) expression in classic and apoptotic circulating tumor cells (CTC) in metastatic castration-resistant prostate cancer (mCRPC).

Karen A. Autio - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Alkaline phosphatase

Circulating tumor cell (CTC) enumeration in patients with metastatic neuroendocrine prostate cancer (NEPC) and castration-resistant prostate cancer (CRPC).

Gurveen Kaur - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

N/A

CK- and small nuclear size circulating tumor cell (CTCs) phenotypes in metastatic castration-resistant prostate cancer (mCRPC).

Roberta Ferraldeschi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Androgen Tear

Expression of prostate-specific membrane antigen (PSMA) on circulating tumor cells (CTCs) in castration-resistant prostate cancer.

Florence Lee - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

N/A

Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy.

Andrew J. Armstrong - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

Circulating biomarkers and outcomes in a single-arm phase II trial of first-line sunitinib alternating with everolimus for advanced renal cell carcinoma (aRCC): EVERSUN ANZUP trial 0901.

Sonia Yip - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Everolimus

Circulating tumor cell kinetics in mRCC patients treated with sunitinib.

Kriti Mittal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Sunitinib

Phase II study of neoadjuvant sorafenib plus cisplatin and gemcitabine (S-CG) for patients with muscle-invasive transitional cell carcinoma of the bladder (MIBC): Results at the end of first stage (NCT01222676).

Andrea Necchi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Transitional cell carcinoma of the bladder

Gemcitabine

Quantification and molecular profiling of circulating tumor cells (CTCs) in urothelial cancer (UC) before and during systemic treatment: Implications across the clinical stages.

Andrea Necchi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

ascrinvacumab

Heterogeneity of circulating tumor cells isolated from bladder cancer patients using ApoStream and biomarkers of epithelial-mesenchymal transition.

Colin P. N. Dinney - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.

Andrew J. Armstrong - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Temsirolimus

Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.

Daniel Peter Petrylak - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

PSMA ADC

Detection and genomic interrogation of circulating tumor cells (CTCs) and circulating tumor stem cells (CTSCs) from men with metastatic castration-resistant prostate cancer (mCRPC).

Terence W. Friedlander - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

N/A

Phase II trial of combination therapy with intravenous carboplatin (C) and oral everolimus (EVE) and prednisone (P) in docetaxel-pretreated (DP) metastatic castrate-resistant prostate cancer (mCRPC): A Prostate Cancer Clinical Trial Consortium study.

Muthu Kumaran Veeraputhiran - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Carboplatin

Multiplexed protein and gene profiling of circulating tumor cells (CTCs) in metastatic castration-resistant prostate cancer (mCRPC) using automated immunofluorescence and fluorescence in situ hybridization.

Dea Nagy - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

N/A

Circulating tumor cells (CTCs) in biochemical recurrence (BR) of prostate cancer: Final results.

Jeanny B. Aragon-Ching - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

A phase II study of linsitinib (OSI-906) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).

Jorge A. Garcia - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

DHEA-S

Prostate-specific mRNA detection in whole blood as an analytically validated prognostic biomarker for patients with castration-resistant prostate cancer (CRPC).

Daniel Costin Danila - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

N/A

Evaluation of PTEN status in circulating tumor cells (CTCs) and matched tumor tissue from patients with castrate-resistant prostate cancer (CRPC).

Elizabeth Punnoose - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Filters

1671 Abstracts